Applied Molecular Evolution is a company seemingly in the right place, with the right technology, at the right time--a beneficiary of Big Pharma's current search for ways to short-cut the discovery process. In the last three months, AME received initial product development milestones from two deals and filed an IND on its own lead product candidate, an improved version of Remicade. Those events validated its technology for optimizing proteins-enough so that partner Eli Lilly decided to buy the firm outright.
Applied Molecular Evolution Inc.
(AME) seems to be in the right place, with the right technology, at
the right time--a beneficiary of Big Pharma's current search for
ways to short-cut the discovery process.
In the last three months, AME received initial product development milestones from two of its deals and filed an IND...